NBT Bank N.A. Buys New Position in Bristol Myers Squibb Company $BMY

NBT Bank N.A. bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the third quarter, HoldingsChannel.com reports. The fund bought 52,930 shares of the biopharmaceutical company’s stock, valued at approximately $3,303,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Eagle Bay Advisors LLC boosted its holdings in Bristol Myers Squibb by 2.6% during the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 168 shares during the period. Boltwood Capital Management grew its position in Bristol Myers Squibb by 2.5% in the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 170 shares during the last quarter. Sandy Cove Advisors LLC grew its position in Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 176 shares during the last quarter. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 27.8% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 818 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 178 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. increased its stake in Bristol Myers Squibb by 2.9% in the third quarter. JGP Global Gestao de Recursos Ltda. now owns 6,333 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 179 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 3.2%

Shares of NYSE BMY opened at $63.10 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The firm has a market capitalization of $128.89 billion, a price-to-earnings ratio of 9.39, a PEG ratio of 0.31 and a beta of 0.19. The stock has a 50 day moving average price of $63.31 and a 200 day moving average price of $60.32. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Fresh clinical updates are putting BMY’s pipeline back in focus ahead of the ESMO 2026 Congress. Recent Phase 3 data in oncology and pulmonary fibrosis, along with the ACTION-1 study meeting its primary endpoint for RYZ101 in certain gastrointestinal neuroendocrine tumors, could support longer-term growth beyond the company’s legacy products. Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
• Positive Sentiment: Bristol Myers Squibb reported strong recent operating momentum, with second-quarter revenue of $12.97 billion, aided by Camzyos and its oncology portfolio. The ACTION-1 result has also strengthened the bullish case ahead of the October 27 earnings release. Bristol-Myers Squibb: Why I’m Bullish Ahead Of Q3 Earnings
• Positive Sentiment: Compared with Pfizer, BMY has delivered a steadier revenue trajectory, with continued year-over-year growth across the reviewed quarters. That consistency may appeal to investors seeking more predictable pharmaceutical revenue. Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
• Positive Sentiment: BMY and the Institute for Healthcare Improvement launched a national collaborative intended to expand access to cancer clinical trials. The initiative may improve trial participation and support the company’s broader oncology research ecosystem over time. IHI and Bristol Myers Squibb Launch National Collaborative
• Neutral Sentiment: Comparisons with Novo Nordisk, Eli Lilly and AbbVie highlight BMY’s stable scale and diversified oncology and cardiovascular portfolio, but also show that competitors have stronger exposure to faster-growing therapies or higher overall revenue growth. Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
• Negative Sentiment: Analysts expect third-quarter earnings to decline and suggest BMY may lack the typical combination of positive earnings and revenue surprises needed for a beat. This creates near-term downside risk around the October 27 report. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline
• Negative Sentiment: Generic competition is increasing across BMY’s mature portfolio, creating pressure on older products. Eliquis remains a growth driver and Revlimid has shown resilience, but investors remain concerned about the durability of legacy-drug revenue. Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BMY. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $73.00 to $59.00 in a report on Monday, October 5th. TD Cowen started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. Bank of America reduced their price target on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research note on Friday, October 9th. Finally, Daiwa Securities Group lifted their price objective on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has an average rating of “Moderate Buy” and an average price target of $64.88.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.